Second patient death reported with gene therapy for muscular dystrophy
Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.
Sarepta reported the death over the weekend and provided additional details about its response, which includes pausing shipments of the therapy, Elevidys, for older patients who are no longer able to walk. The one-time treatment is approved for children with a genetic variant of Duchenne's muscular dystrophy, which causes weakness, loss of mobility and early death in males.
Elevidys is the first gene therapy approved in the U.S. for the rare muscle-wasting condition, but it has faced scrutiny since its accelerated approval in 2023.
The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy. Older patients receive a larger dose of the therapy.
Sarepta said it would pause a study in those patients and assemble an expert panel to recommend new safety protocols for taking the drug. Those changes are expected to include increased use of immune-system suppressing drugs, company executives said Monday. The liver injury associated with the therapy is thought to be connected to the immune system's response.
Sarepta said it was cooperating with the Food and Drug Administration, which would have to sign off on any changes to the product's use.
Elevidys received expedited approval despite concerns from some FDA scientists about its effectiveness in treating Duchenne's.
The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, regardless of whether they are still able to walk. Previously it was only available for younger patients who were still walking.
Shares of the Cambridge, Massachusetts-based company fell more than 42% to close at about $21 in trading.
Wall Street analysts speculated that FDA officials, including new vaccine chief Dr. Vinay Prasad, might impose more restrictions on the drug or even block its use. Prasad has been highly critical of the therapy since its approval under the agency's previous leadership.
'Now with two deaths reported in this segment of the market, it seems incrementally more possible that the FDA could step in and remove the therapy from the market in non-ambulatory patients,' said Leerink Partners analyst Joseph Schwartz, in a Sunday research note.
Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time infusion.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
30 minutes ago
- The Guardian
CDC official in charge of Covid data resigns ahead of vaccine meeting
The scientist responsible for overseeing the CDC team that collects data on Covid and RSV hospitalizations resigned on Monday. Dr Fiona Havers told colleagues in an email that she no longer had confidence the data would be used 'objectively or evaluated with appropriate scientific rigor to make evidence-based vaccine policy decisions', according to Reuters. She resigned before a planned meeting of a new vaccine panel put in place by Robert Kennedy Jr after he fired all 17 members of the CDC's independent vaccine advisory panel. Kennedy also dropped a recommendation to get the Covid shot for healthy children and pregnant women. Havers, leader of the Resp-Net hospitalization surveillance team, did not respond to requests for comment. Her resignation follows moves by Kennedy, the health secretary, to abruptly fire all 17 members of the CDC's independent vaccine advisory panel and drop a recommendation for administering Covid shots to healthy children and pregnant women. Kennedy, who has long sown doubt about the safety and efficacy of vaccines, replaced the advisory board with eight members of his own choosing, some of whom have histories of objecting to Covid shots or vaccines in general. Havers said in her email that the Covid and RSV data collected by her team had been used in more than 20 peer-reviewed manuscripts and 15 Morbidity and Mortality Weekly Reports issued by the CDC. The newly installed vaccine panel, known as the advisory committee on immunization practices, is expected to meet 25-27 June to vote on the use of Covid-19 boosters and other vaccines by the American public. A Health and Human Services spokesperson told Reuters that the agency is committed to 'gold standard science' and that the vaccine policy will be based on objective data, transparent analysis and evidence.
Daily Mail
an hour ago
- Daily Mail
Pennsylvania Boy, 10, dies of heart attack just a day after he helped baseball team win championship
A 10-year-old baseball player who helped his team secure a championship win has died from a heart attack, leaving a Pennsylvania community reeling. Bryson Funk, of Linglestown, passed away on Thursday after suffering from a cardiac arrest linked to myocarditis, which causes inflammation in the middle layer of the heart's wall. His family told CBS 21 he was born with congenital heart defects - coarctation of the aorta and a deformed bicuspid aortic valve - but doctors said these conditions had nothing to do with his death. Just a day before the unexpected tragedy, the little league athlete pitched the final three innings of his team's championship game. He struck out the opponents' last batter and lead the Colts to victory. 'Bryson was quite the athlete,' Nicki Branther, one of Bryson's relatives wrote on a GoFundMe page created to cover funeral expenses. The shocking death has rattled his friends, teammates and loved ones, who have taken to social media to honor the 'vibrant' and 'active' young man. 'Yesterday, our baseball family lost a shining light far too soon,' the Lower Paxton Township Community shared in a heartbreaking Facebook tribute on Friday. 'He brought energy, kindness, and a true love for the game to every field he stepped on.' The Linglestown Baseball Association described Bryson as a 'vibrant and talented All-Star' who 'brought energy, kindness, and a true love for the game to every field he stepped on.' His team brought Bryson's jersey to games over the weekend, honoring the player gone too soon. Bryson was not only a talented pitcher, but a valued addition to the 717 Athletics cheerleading team. 'Bryson brought so much joy, laughter, and light into the lives of all who knew him,' the team wrote. 'His time with us was far too short, but the love he gave and the memories he created will forever live on in our hearts.' The Peyton Walker Foundation, a nonprofit group committed to raising awareness to Sudden Cardiac Arrest (SCA) among young people and advocates for regular heart screenings, also addressed Bryson's death. The organization said: 'We are heartbroken at the Peyton Walker Foundation to learn of the tragic loss of Bryson Funk, a young athlete in our community. 'Our hearts go out to the family, friends, and all who are grieving. Please keep them in your thoughts and prayers during this incredibly difficult time.' Roughly 2,000 kids die from SCA each year in the US, according to the Children's Hospital of Philadelphia. These sudden heart attacks are most common among males between the ages of 10 and 19. While SCA is considerably rare, it accounts for up to five percent of deaths among five to 19-year-olds, Johns Hopkins reported. In addition to the GoFundMe, which has raised more than $42,000, a Meal Train was created to support Bryson's grieving parents, Todd and Amy, and his younger sister.
The Independent
an hour ago
- The Independent
Purdue Pharma to pay $7.4 billion in opioid lawsuit settlement
Purdue Pharma and its owners, the Sackler family, are set to pay $7.4 billion to settle lawsuits regarding the drug company's manufacturing and distribution of opioids. The Sackler family and its company had agreed to bump up their settlement contribution to $7.4 billion in January. On Monday, officials announced the attorneys general in all 50 states, Washington, D.C. and four U.S. territories agreed to the settlement. Besides the hefty financial reward, the settlement also ends the Sacklers' ownership of Purdue Pharma and their ability to sell opioids in the U.S. For years, Purdue Pharma and the Sackler family have been facing the legal and financial consequences of what prosecutors said was its role in fueling a nationwide opioid epidemic with the OxyContin painkiller. Purdue Pharma started manufacturing the drug in the mid-90s, and in 2007, three current and former company executives pleaded guilty to misleading the public about the drug's risk of addiction. Drug overdose deaths involving prescription opioids rose from under 3,500 in 1999 to more than 17,000 in 2017, according to the National Institute on Drug Abuse. Drug overdose deaths in general had a record year-to-year decline in 2024, with fewer than 30,000 fatal overdoses than in 2023. In 2019, Purdue Pharma filed for bankruptcy protection after more than 2,600 lawsuits were filed against it. The newly agreed-upon $7.4 billion settlement is a show of strength and unity among the justice system against the nation's deadly opioid crisis. From coast to coast, attorneys general celebrated the victory over Purdue Pharma and the Sackler family. New York Attorney General Letitia James said Monday when announcing the settlement agreement: 'For decades, the Sacklers put profits over people, and played a leading role in fueling the epidemic of opioid addictions and overdoses. While no amount of money can fully heal the destruction they caused, these funds will save lives and help our communities fight back against the opioid crisis. I will continue to work to deliver justice for all those affected by opioid addiction.' New York will receive up to $250 million through the settlement. California Attorney General Rob Bonta said in a statement Monday: 'The opioid epidemic has ravaged communities in California and across the country. The companies and individuals who fueled this crisis must be held accountable. With today's announcement, the California Department of Justice is continuing to deliver results for our communities.' The Golden State will receive up to $440 million from the settlement.
